In a patient with severe dementia-related agitation who is currently on multiple medications, which medication should be added or discontinued to help manage the agitation?

Medication Management for Severe Dementia-Related Agitation

Before adding any medication for agitation, systematically review and discontinue medications that may be worsening agitation—particularly anticholinergics, benzodiazepines, and other CNS-active drugs—then implement non-pharmacological interventions, and only if agitation remains severe, dangerous, or causes significant distress should you add low-dose risperidone or brexpiprazole after informed discussion of mortality and stroke risks. 1

Step 1: Medication Review and Discontinuation

First, identify and remove potential aggravating medications from the current regimen:

• Anticholinergic medications (antihistamines, tricyclic antidepressants, bladder antimuscarinics, muscle relaxants)
• Benzodiazepines (can paradoxically worsen agitation)
• Medications causing delirium (opioids, corticosteroids, H2-blockers)
• Dopaminergic agents if not essential
• Stimulants or activating antidepressants if present

This step alone may resolve or significantly reduce agitation without adding new medications 1, 2.

Step 2: Address Medical Contributors

Assess and treat:

• Pain (often undertreated and a major agitation trigger)
• Urinary retention or constipation
• Infections (UTI, pneumonia)
• Metabolic disturbances
• Sleep disruption

Consider trazodone 25-50 mg at bedtime if insomnia or sundowning is contributing 3.

Step 3: Non-Pharmacological Interventions (Mandatory First-Line)

These must be attempted before antipsychotics unless the situation is dangerous 1:

• Identify and eliminate environmental triggers
• Structured daily activities matched to patient's interests and functional level
• Music therapy, reminiscence therapy, or sensory interventions
• Caregiver education on de-escalation techniques
• Environmental modifications (reduce noise, improve lighting, simplify surroundings)

Document the specific interventions tried and their outcomes before proceeding to pharmacotherapy 1.

Step 4: Pharmacological Treatment (Only When Necessary)

When to Add Medication

Antipsychotics should only be used when 1:

• Agitation is severe, dangerous, or causes significant patient distress
• Non-pharmacological interventions have been inadequate
• After informed discussion with patient (if feasible) and surrogate decision-maker about increased mortality risk (1.4-fold increase) and stroke risk

Medication Selection

First-line pharmacological options:

1. Brexpiprazole (FDA-approved for agitation in Alzheimer's dementia)

   • Start 0.5 mg daily, titrate to 1-2 mg daily
   • Strongest evidence and most favorable safety profile among antipsychotics 4, 5
   • Only FDA-approved agent specifically for this indication

2. Risperidone (if brexpiprazole unavailable or cost-prohibitive)

   • Start 0.25 mg daily, maximum 1 mg daily
   • Most robust evidence for efficacy (OR 1.96 for response) 6, 7
   • Monitor closely for extrapyramidal symptoms (39% increased risk) and cerebrovascular events 7

3. Citalopram (when safety is prioritized over efficacy)

   • Start 10 mg daily, maximum 20 mg daily (NOT 30 mg due to QT prolongation)
   • Modest efficacy (OR 1.61 for SSRIs as class) but better safety profile than antipsychotics 6, 3
   • Mandatory EKG monitoring for QT interval
   • Consider if cardiovascular risk is lower concern than extrapyramidal effects

Medications to AVOID

• Haloperidol: Inferior efficacy compared to all other options 6
• Oxcarbazepine: Poor acceptability/tolerability 6
• Quetiapine: Despite common use, limited evidence of efficacy 7, 3
• Benzodiazepines: Worsen cognition and increase fall risk

Step 5: Monitoring and Reassessment

Use a quantitative measure (e.g., Cohen-Mansfield Agitation Inventory, Neuropsychiatric Inventory) to track response 1.

At 4 weeks:

• If no clinically significant response → taper and discontinue the antipsychotic 1
• If significant side effects occur → reassess risk/benefit and consider discontinuation 1

At 8-12 weeks (if effective):

• Attempt gradual taper to determine if continued treatment is necessary
• Many patients can be successfully withdrawn after symptom stabilization 1

Critical Safety Warnings

All antipsychotics in dementia carry:

• 36% increased mortality risk (moderate-certainty evidence) 7
• 32% increased serious adverse event risk 7
• 93% increased somnolence risk 7
• 39% increased extrapyramidal symptom risk 7
• Black box warning from FDA

These risks must be explicitly discussed and documented before prescribing 1.

Common Pitfalls to Avoid

• Starting antipsychotics without attempting non-pharmacological interventions
• Using doses higher than recommended (always start low, go slow)
• Continuing ineffective medications beyond 4 weeks
• Failing to reassess need for continued treatment after stabilization
• Not monitoring for side effects with objective measures
• Prescribing without informed consent discussion about mortality risk
• Using haloperidol as first-line (outdated practice with poor evidence)